recombinant influenza hemagglutinin

Vaccineexperimental

Clinical trial activity

4 trials · 12 clinical orgs · 0 marketing orgs

Phase 1
4
Phase 2
0
Phase 3
0
Phase 4
0

Earliest trial started Jul 1, 2015 (NCT02335164)

Timeline

2010s

  1. Jan 1, 2015

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Also known as

  • recombinant influenza hemagglutinin

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06149091Early Phase 1 (Phase 1)Dec 1, 2023Harbin Medical University, Nanchang University, Peking University
NCT03300050Phase 1Oct 10, 2017Duke University, GlaxoSmithKline, Icahn School of Medicine at Mount Sinai, PATH, The EMMES Corporation, University of Cincinnati
NCT03038776Phase 1Jan 1, 2017Australian Respiratory and Sleep Medicine Institute, Flinders University, Vaxine Pty Ltd
NCT02335164Phase 1Jul 1, 2015Australian Respiratory and Sleep Medicine Institute, Flinders University, Vaxine Pty Ltd
Showing 4 of 4 trials
Page 1 / 1

Organizations

Research & Development (12)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Australian Respiratory and Sleep Medicine InstituteAcademic/Hospital2012015
Flinders UniversityAcademic/Hospital2012015
Vaxine Pty LtdFor profit2212015
Duke UniversityAcademic/Hospital1012017
GlaxoSmithKlineFor profit1012017
Harbin Medical UniversityAcademic/Hospital1012023
Icahn School of Medicine at Mount SinaiAcademic/Hospital1012017
Nanchang UniversityAcademic/Hospital1012023
PATHAcademic/Hospital1112017
Peking UniversityAcademic/Hospital1112023
The EMMES CorporationFor profit1012017
University of CincinnatiAcademic/Hospital1012017
12 organizations
Page 1 / 1